Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.52 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.52 |
| ▸ | PDE8A | O60658 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100993 | 0.87 | PDE7A (0.55) | PDE7APDE7BPDE8ATSHRCRHBP | |
| SCHEMBL100103 | 0.87 | PDE7A (0.55) | PDE7APDE7BPDE8ATSHRCRHBP | |
| SCHEMBL100396 | 0.86 | PDE7A (0.53) | PDE7APDE7BPDE8ATSHRCRHBP | |
| SCHEMBL32681322 | 0.86 | PDE7A (0.53) | PDE7APDE7BPDE8ATSHRCRHBP | |
| SCHEMBL101167 | 0.85 | PDE7A (0.53) | PDE7APDE7BPDE8ATSHRCRHBP | |
| SCHEMBL100395 | 0.84 | PDE7A (0.62) | PDE7APDE7BPDE8A | |
| SCHEMBL30837936 | 0.84 | PDE7A (0.62) | PDE7APDE7BPDE8A | |
| SCHEMBL173205 | 0.84 | PDE7A (0.52) | PDE7APDE7BPDE8ATSHRCRHBP | |
| SCHEMBL30837867 | 0.83 | PDE7A (0.58) | PDE7APDE7BPDE8A | |
| SCHEMBL100928 | 0.83 | PDE7A (0.58) | PDE7APDE7BPDE8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242126-B2 | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2012-08-14 | — | — | US | disclosed |
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | PPARD, DPP4, NDUFB7 | PDE7A 941/4885PDE7B 1077/4885PDE8A 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.